2001, Number S1
<< Back Next >>
Rev Med Hosp Gen Mex 2001; 64 (S1)
COXIB’s Pharmacology. Selectivity vs. Specificity
Luján M, López y ME, Guajardo R, Castañeda JL, Tena S, Juárez M, Ibáñez Y
Language: Spanish
References: 9
Page: 13-15
PDF size: 62.33 Kb.
Text Extraction
No abstract
REFERENCES
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971: 231: 232-5.
Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 1988; 38: 97-120.
Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134-43.
Needleman P, Isakson PC. The discover and function of COX-2. J Rheumatol 1997 Suppl; 49: 6-8.
4a. Marnett L, Kaltgutkar AS. Cyclooxygenase-2 inhibitors: discovery, selectivity and the future. Trends Pharmacol Sci 1999; 20: 465-9.
Lipsky PE, Brooks P, Crofford LJ, Dubois R et al. Unresolved issues in the role of cyclooxygense-2 in normal physiologic process and disease. Arch Intern Med 2000; 160: 913-20.
Vane JR, Warner TD. Nomenclature for COX-2 inhibitors. Lancet 2000; 356: 1373-4.
Lichtenstein DR, Wolf M. COX-2 selective NSAIDs: New and improved? JAMA 2000; 284:1297-9.
Alarcón Ginori A, Barreda R. Celecoxib vs Naproxeno, eficacia y tolerabilidad en osteoartrosis. Estudio multicéntrico, comparativo, doble ciego aleatorizado. Rev Mex Reumat 2000; 15: 95-105.
Full text